Health Care Journals | Open Access - Edelweiss | Edelweiss Publications

Edelweiss: Cancer Open Access (ISSN: 2689-6737)

Cellular immunotherapy

Cellular immunotherapy is an innovative treatment approach that provokes bodys own immune system to fight against the cancer. cellular immunotherapy, including chimeric antigen receptor (CAR) T-cell therapy, T-cell receptor (TCR) therapy, tumor-infiltrating lymphocytes (TIL) therapy, dendritic cell vaccine

Dendritic cell therapy: Dendritic cell therapy provokes anti-tumor responses by causing dendritic cells to present tumor antigens to lymphocytes, which activates them, priming them to kill other cells that present the antigen.

CAR T-cell therapy: can be used to treat B-cell lymphoma, mantle cell lymphoma, acute lymphoblastic leukemia, transformed follicular lymphoma and follicular lymphoma.

TCR gene transfers: require human leukocyte antigen matching, can be used to treat several types of malignancies, including lung cancer, sarcomas and multiple myeloma.

TIL therapy: can be used to treat malignant melanoma, head and neck squamous cell carcinoma, genitourinary carcinoma and lung cancer.

 Edelweiss: Cancer Open Access is an open access journal which aims to publish most complete and genuine source of information in the form of short commentary, mini review, case report, related, but not limited to above areas and making them available freely through online without any subscriptions and restrictions to researches worldwide

Editorial Board

Jhon Smith

Professor

editor
Jhon Smith

Professor

editor
Jhon Smith

Assistant Professor

editor
Jhon Smith

Professor

editor